TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2025

Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study.

Lingfang Xia et al.PubMed ↗Publisher ↗

No numbers read from the abstract.